{
    "id": "dbpedia_6280_0",
    "rank": 81,
    "data": {
        "url": "https://link.springer.com/10.1007/978-3-030-62059-2_45",
        "read_more_link": "",
        "language": "en",
        "title": "Mood Stabilizers: Lithium",
        "top_image": "https://static-content.springer.com/cover/book/978-3-030-62059-2.jpg",
        "meta_img": "https://static-content.springer.com/cover/book/978-3-030-62059-2.jpg",
        "images": [
            "https://link.springer.com/oscar-static/images/darwin/header/img/logo-springerlink-39ee2a28d8.svg",
            "https://media.springernature.com/w72/springer-static/cover-hires/book/978-3-030-62059-2?as=webp",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-319-56015-1?as=webp",
            "https://media.springernature.com/w215h120/springer-static/image/art%3Aplaceholder%2Fimages/placeholder-figure-nature.png",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-319-56015-1?as=webp",
            "https://link.springer.com/oscar-static/images/logo-springernature-white-19dd4ba190.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Janusz K. Rybakowski",
            "Janusz K"
        ],
        "publish_date": "2022-08-16T00:00:00",
        "summary": "",
        "meta_description": "The developmental history of lithium and its physicochemical properties, pharmacokinetics, and mechanisms of action are presented. Among the latter, the effect on the phosphatidylinositol (PI) system and the inhibition of the glycogen synthase kinase 3beta...",
        "meta_lang": "en",
        "meta_favicon": "/oscar-static/img/favicons/darwin/apple-touch-icon-92e819bf8a.png",
        "meta_site_name": "SpringerLink",
        "canonical_link": "https://link.springer.com/referenceworkentry/10.1007/978-3-030-62059-2_45",
        "text": "Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol. 2005;28:38–48.\n\nAlda M. Pharmacokinetics of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. The comprehensive guide. Boca Raton: Taylor & Francis; 2006. p. 321–8.\n\nAlda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry. 2015;20:661–70.\n\nArfwedson A. Untersuchungen einiger bei der Eisen Grube von Utö vorkommenden Fossilien und von einem darin gefundenen neuen feuerfesten Alkali. Schweiggers Journal für Chemie und Physik. 1818;22:93–120.\n\nBaastrup PC. The use of lithium in manic-depressive psychoses. Compr Psychiatry. 1964;5:396–408.\n\nBaastrup PC, Schou M. Lithium as a prophylactic agent. Its effect against recurrent depression and manic-depressive psychosis. Arch Gen Psychiatry. 1967;16:162–72.\n\nBauer MS, Mitchner L. What is a “mood stabilizer”? An evidence-based response. Am J Psychiatry. 2004;161:3–18.\n\nBauer M, Grof P, Müller-Oerlinghausen B. Lithium in neuropsychiatry. The comprehensive guide. Boca Raton: Taylor & Francis; 2006.\n\nBauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 2014;28:331–42.\n\nBerridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989;59:411–9.\n\nBierbrauer J, Albrecht J, Müller-Oerlinhausen B. Lithium and its cardiovascular effects. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. The comprehensive guide. Boca Raton: Taylor & Francis; 2006. p. 295–301.\n\nBaldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625–39.\n\nBlackwell B, Shepherd M. Prophylactic lithium: another therapeutic myth? An examination of the evidence to date. Lancet. 1968;291:968–71.\n\nBlüml V, Regier MD, Hlavin G, Rockett IR, König F, Vyssoki B, et al. Lithium in the public water supply and suicide mortality in Texas. J Psychiatr Res. 2013;47:407–11.\n\nCade JFK. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;36:349–52.\n\nChen TY, Kamali M, Chu CS, Yeh CB, Huang SY, Mao WC, et al. Divalproex and its effect on suicide risk in bipolar disorder: a systematic review and meta-analysis of multinational observational studies. J Affect Disord. 2019;245:812–8.\n\nCipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306–15.\n\nCoppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord. 1991;23:1–7.\n\nCrossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935–40.\n\nCipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. Br Med J. 2013;346:f3646.\n\nDe Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant nonresponders. Br J Psychiatry. 1981;138:262–56.\n\nDelay J, Deniker P, Harl J-M. Utilisation en thérapeutique psychiatrique d’une phénothiazine d’action centrale elective. Ann Méd-Psychol. 1952;110:112–31.\n\nDickerson FB, Boronow JJ, Stallings C, Origoni AE, Cole S, Krivogorsky B, et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry. 2004;55:588–93.\n\nDonix M, Bauer M. Population studies of association between lithium and risk of neurodegenerative disorders. Curr Alzheimer Res. 2016;13:873–8.\n\nDuke P, Hochman G. A brilliant madness; living with manic-depressive illness. New York: Bantam Books; 1992.\n\nDuke P, Turan K. Call me Anna: the autobiography of Patty Duke. New York: Bantam Books; 1987.\n\nFajardo VA, Fajardo VA, LeBlanc PJ, MacPherson REK. Examining the relationship between trace lithium in drinking water and the rising rates of age-adjusted Alzheimer’s disease mortality in Texas. J Alzheimers Dis. 2018;61:425–34.\n\nFelber W. Die Lithiumprophylaxe der Depression vor 100 Jahren – ein genialem Irrtum. Fortschr Neurol Psychiatr. 1987;55:141–4.\n\nFerensztajn-Rochowiak E, Kucharska-Mazur J, Tarnowski M, Samochowiec J, Ratajczak MZ, Rybakowski JK. Stem cells, pluripotency and glial cell markers in peripheral blood of bipolar patients on long-term lithium treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;80:28–33.\n\nFinley PR. Drug interactions with lithium: an update. Clin Pharmacokinet. 2016;55:925–41.\n\nGarrod AB. Gout and rheumatic gout. London: Walton and Maberly; 1859.\n\nGeddes JR, Burgess S, Kawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217–22.\n\nGerdtz J. Mental illness and the Roman physician: the legacy of Soranus of Ephesus. Hosp Community Psychiatry. 1994;45:485–7.\n\nGeddes JR, Goodwin GM, Rendell J Azorin J-M, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomized open-label trial. Lancet. 2010;375:385–95.\n\nGermana C, Kempton MJ, Sarnicola A, Christodoulou T, Haldane M, Hadjulis M, et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatr Scand. 2010;122:481–7.\n\nGitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4:27.\n\nGoodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432–41.\n\nGrof P. Excellent lithium responders: people whose lives have been changed by lithium prophylaxis. In: Birch NJ, Gallicchio VS, Becker RW, editors. Lithium: 50 years of psychopharmacology, new perspectives in biomedical and clinical research. Cheshire: Weidner Publishing Group; 1999. p 36–51.\n\nGrof P. Sixty years of lithium responders. Neuropsychobiology. 2010;62:27–35.\n\nHajek T, Weiner MW. Neuroprotective effects of lithium in human brain? Food for thought. Curr Alzeimer Res. 2016;13:862–72.\n\nHajek T, Bauer M, Simhandl C, Rybakowski J, O’Donovan C, Pfennig A, et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med. 2014;44:507–17.\n\nHammond WA. Treatise on diseases of the nervous system. New York: Appleton; 1871.\n\nHartigan GP. The use of lithium salts in affective disorders. Br J Psychiatry. 1963;109:810–4.\n\nHawking S. A brief history of time. From the Big Bang to back holes. New York: Bantam Books; 1988.\n\nHou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387:1085–93.\n\nInternational Consortium on Lithium Genetics (ConLi+Gen), Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, et al. Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: a genome-wide association study. JAMA Psychiat. 2018;75:65–74.\n\nJamison KR. An unquiet mind. A memoir of moods and madness. New York: Alfred A. Knopf; 1996.\n\nJope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci. 2011;4:16.\n\nKapusta ND, Mossaheb N, Etzersdorfer E, Hlavin G, Thau K, Willeit M, et al. Lithium in drinking water and suicide mortality. Br J Psychiatry. 2011;198:346–50.\n\nKatagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. Curr Med Res Opin. 2012;28:701–13.\n\nKessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and the risk of dementia. Arch Gen Psychiatry. 2008;65:1331–5.\n\nKessing LV, Forman JL, Andersen PK. Does lithium protect against dementia ? Bipolar Disord. 2010;12:97–4.\n\nKessing LV, Gerds TA, Knudsen NN, Jørgensen LF, Kristiansen SM, Voutchkova D, et al. Association of lithium in drinking water with the incidence of dementia. JAMA Psychiat. 2017;74:1005–10.\n\nKessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord. 2018; https://doi.org/10.1111/bdi.12623.. [Epub ahead of print]\n\nKetter TA, Miller S, Dell’Osso B, Wang PW. Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord. 2016;191:256–73.\n\nKraszewska A, Ziemnicka K, Jończyk-Potoczna K, Sowiński J, Rybakowski JK. Thyroid structure and function in long-term lithium-treated and lithium-naïve bipolar patients. Hum Psychopharmacol. 2019a;34:e2708.\n\nKraszewska A, Ziemnicka K, Sowiński J, Ferensztajn-Rochowiak E, Rybakowski JK. No connection between long-term lithium treatment and antithyroid antibodies. Pharmacopsychiatry. 2019b;52:232–6.\n\nKleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology. 2000;42(suppl 1):2–10.\n\nKraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 6th ed. Leipzig: Barth; 1899.\n\nKraszewska A, Abramowicz M, Chłopocka-Woźniak M, Sowiński J, Rybakowski J. The effect of lithium on thyroid function in patients with bipolar disorder. Psychiatr Pol. 2014;48:417–28.\n\nKraszewska A, Chlopocka-Wozniak M, Abramowicz M, Sowinski J, Rybakowski JK. A cross-sectional study of thyroid function in 66 patients with bipolar disorder receiving lithium for 10–44 years. Bipolar Disord. 2015;17:375–80.\n\nLange C. Om Periodiske Depressionstilstande og deres Patogenese. Lund: Copenhagen; 1886.\n\nLange C. Periodische Depressionzustände und ihre Pathogenesis auf dem Boden der harnsäuren Diathese. Hamburg/Leipzig: Verlag von Leopold Voss; 1895.\n\nLeroy K, Ando K, Heraud C, Yilmaz Z, Authelet M, Boeynaems JM, et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis. 2010;19:705–19.\n\nLewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M. The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review. Int J Bipolar Disord. 2015;3:32.\n\nLopez-Jaramillo C, Lopera-Vasquez J, Ospina Duque J, et al. Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiatry. 2010;71:1055–60.\n\nLuria SE. A slot machine, a broken test tube: an autobiography. New York: Harper and Row; 1984.\n\nLyoo K, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL, et al. Lithium-induced grey matter volume increase as a neural correlate of treatment response in bipolar disorder. A longitudinal brain imaging study. Neuropsychopharmacology. 2010;35:1743–50.\n\nMachado-Vieira R. Lithium, stress, and resilience in bipolar disorder: deciphering this key homeostatic synaptic plasticity regulator. J Affect Disord. 2018;233:92–9.\n\nMalhi GS, Outhred T. Therapeutic mechanisms of lithium in bipolar disorder: recent advances and current understanding. CNS Drugs. 2016;30:931–49.\n\nManchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) report. PLoS One. 2013;8:e65636.\n\nMann L, Heldman E, Bersudsky Y, Vatner SF, Ishikawa Y, Almog O, et al. Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. Bipolar Disord. 2009;11:885–96.\n\nMarcus R, Khan A, Rollin L, Morris B, Timko K, Carson W. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011;13:133–44.\n\nMatsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N. Lithium as a treatment for Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2015;48:403–10.\n\nMoncrieff J. Lithium: evidence rconsidered. Br J Psychiatry. 1997;171:113–9.\n\nMoore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet. 2000;356:1241–2.\n\nMüller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand. 1992;86:218–22.\n\nMunk-Olsen T, Liu X, Viktorin A, Brown HK, Di Florio A, D’Onofrio BM, et al. Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry. 2018;5:644–52.\n\nNassar A, Azab AN. Effects of lithium on inflammation. ACS Chem Neurosci. 2014;5:451–8.\n\nNivoli AMA, Murru A, Vieta E. Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuropsychobiology. 2010;62:27–35.\n\nNocjar C, Hammonds MD, Shim SS. Chronic lithium treatment magnifies learning in rats. Neuroscience. 2007;150:774–88.\n\nNunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res. 2013;10:104–7.\n\nOhgami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br J Psychiatry. 2009;195:464–5.\n\nPasquali L, Busceti CL, Fulceri F, Paparelli A, Fornai F. Intracellular pathways underlying the effects of lithium. Behav Pharmacol. 2010;21:473–92.\n\nPermoda-Osip A, Abramowicz M, Kraszewska A, Suwalska A, Chłopocka-Woźniak M, Rybakowski JK. Kidney, thyroid and other organ functions after 40 years or more of lithium therapy: a case series of five patients. Ther Adv Psychopharmacol. 2016;6:277–82.\n\nPisanu C, Papadima EM, Del Zompo M, Squassina A. Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: potential involvement of epigenetics. Neurosci Lett. 2018;669:24–31.\n\nQuiroz JA, Machado-Vieira R, Zarate CA, Manji HK. Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010;62:50–60.\n\nRadomski J, Fuyat HN, Nelson AA, Smith PK. The toxic effects, excretion and distribution of lithium chloride. J Pharmacol Exp Ther. 1950;100:429–40.\n\nRemlinger-Molenda A, Wojciak P, Michalak M, Karczewski J, Rybakowski JK. Selected cytokine profiles during remission in bipolar patients. Neuropsychobiology. 2012;66:193–8.\n\nRybakowski JK. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry. 2000;33:159–64.\n\nRybakowski JK. Two generations of mood stabilizers. Int J Neuropsychopharmacol. 2007;10:709–11.\n\nRybakowski JK. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs. 2013;27:165–73.\n\nRybakowski JK. Neurological, cognitive and neuroprotective effects of treatment used in bipolar disorder. In: Yildiz A, Ruiz P, Nemeroff CB, editors. The bipolar book. History, neurobiology and treatment. New York: Oxford University Press; 2015. p. 403–15.\n\nRybakowski JK. Effect of lithium on neurocognitive functioning. Curr Alzheimer Res. 2016;13:887–93.\n\nRybakowski JK. Meaningful aspects of the term ‘mood stabilizer’. Bipolar Disord. 2018;20:391–2.\n\nRybakowski JK, Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium. 1991;2:43–7.\n\nRybakowski J, Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. Eur Neuropsychopharmacol. 1992;2:161–5.\n\nRybakowski JK, Chłopocka-Woźniak M, Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord 2001;3:63–67.\n\nRybakowski JK, Suwalska A. Gastrointestinal, metabolic and body weight changes during treatment with lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. The comprehensive guide. Boca Raton: Taylor & Francis; 2006. p. 283–94.\n\nRybakowski JK, Permoda-Osip A, Borkowska A. Response to prophylactic lithium in bipolar disorder may be associated with a preservation of executive cognitive functions. Eur Neuropsychopharmacol. 2009;19:791–5.\n\nRybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol. 2010;13:617–22.\n\nRybakowski J, Drogowska J, Abramowicz M, Chłopocka-Woźniak M, Czekalski S. The effect of long-term lithium treatment on kidney function. Psychiatr Pol. 2012;46:627–36.\n\nRybakowski JK, Dmitrzak-Weglarz M, Kliwicki S, Hauser J. Polymorphism of circadian clock genes and prophylactic lithium response. Bipolar Disord. 2014;16:151–8.\n\nRybakowski JK, Suwalska A, Hajek T. Clinical perspectives of lithium’s neuroprotective effect. Pharmacopsychiatry. 2018;51:194–9.\n\nSchou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17:250–60.\n\nSchou M, Kampf D. Lithium and the kidneys. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry. The comprehensive guide. Boca Raton: Taylor & Francis; 2006. p. 251–8.\n\nSchou M, Thompsen K. Lithium prophylaxis of recurrent endogenous affective disorders. In: Johnson FN, editor. Lithium research and therapy. London: Academic; 1976. p. 63–84.\n\nSchou M, Amdisen A, Eskjaer Jensen S, Olsen T. Occurrence of goitre during lithium treatment. Br Med J. 1968;3:710–3.\n\nSchulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET, et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology. 2010;62:72–8.\n\nSeverus E, Bauer M. Managing the risk of lithium-induced nephropathy in the long-term treatment of patients with recurrent affective disorders. BMC Med. 2013;11:34.\n\nSeverus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.\n\nSkinner GRB, Hartley C, Buchan A, Harper L, Gallimore P. The effect of lithium chloride on the replication of herpes simplex virus. Med Microbiol Immunol. 1980;168:258–65.\n\nSofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet. 2010;6:pii: e1001087.\n\nStorosum JG, Wohlfarth T, Schene A, Elferink A, van Zwieten BJ, van den Brink W. Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar Disord. 2007;9:793–8.\n\nSuppes T, Vieta E, Gustafsson U, Ekholm B. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety. 2013;30:1089–98.\n\nTondo L, Abramowicz M, Alda M, Bauer M, Bocchetta A, Bolzani L, et al. Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. Int J Bipolar Disord. 2017;5:27.\n\nUndurraga J, Sim K, Tondo L, Gorodischer A, Azua E, Tay KH, et al. Lithium treatment for unipolar major depressive disorder: systematic review. J Psychopharmacol. 2019;33:167–76.\n\nWilliams R, Ryves WJ, Dalton EC, Eickholt B, Shaltiel G, Agam G, et al. A molecular cell biology of lithium. Biochem Soc Trans. 2004;32(Pt 5):799–802.\n\nWingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effect of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry. 2009;70:1588–97."
    }
}